← Eichor
Study identifier: NCT06173219 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.

Condition: Advanced Solid Tumor  ·  Sponsor: China-Japan Friendship Hospital

PhasePhase 1/Phase 2
Planned participants38
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance. The main questions it aims to answer is: the safety and efficacy of the new regimen for advanced multiple metastatic solid tumors standard treatment failure/drug resistance, and explore the impact on immune function. Participants will receive the combination of radiotherapy and immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Guangying Zhu, M.D.  ·  +86-010 84205381  ·  zryyfa@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

China-Japan Friendship HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06173219